Morgan Stanley analyst Tejas Savant maintains $Natera (NTRA.US)$ with a buy rating, and maintains the target price at $176.
According to TipRanks data, the analyst has a success rate of 40.0% and a total average return of -4.5% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Natera (NTRA.US)$'s main analysts recently are as follows:
The stock's valuation is seen as fully warranted by several catalysts that are expected to drive both near-term and long-term upside in estimates. This view is based on the recent quarterly results, the updated projections for 2024, and the initial insights provided for 2025 during the management's discussion.
Natera has reported yet another robust quarter, according to an analyst. It is noted that the company is excelling across various metrics, including volume, selling price, margin, and cash management, with potential for even greater enhancements looking towards 2025. The sustained strong performance reinforces the belief that Natera stands out as a premier entity within the diagnostics sector.
The company's Q3 results were exceptionally strong, continuing the trend of improving fundamentals. The company is channeling its operating cash flow back into the business, thereby strengthening its leadership in sales, marketing, medical affairs, and legal aspects.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
摩根士丹利分析師Tejas Savant維持$Natera (NTRA.US)$買入評級，維持目標價176美元。
根據TipRanks數據顯示，該分析師近一年總勝率為40.0%，總平均回報率為-4.5%。
此外，綜合報道，$Natera (NTRA.US)$近期主要分析師觀點如下：
股票的估值被認爲是完全合理的，預計將推動短期和長期預期的增長的幾個催化劑支撐。這一觀點基於最近的季度業績，2024年更新的預測，以及管理層討論中對2025年初步提供的見解。
根據一位分析師的說法，Natera又一季度表現強勁。據悉，該公司在各種指標上表現出色，包括成交量、售價、利潤率和現金管理，展望2025年有更大的提升潛力。持續強勁的業績強化了Natera在診斷板塊中獨樹一幟的信念。
公司第三季度的業績異常強勁，延續了基本面不斷改善的趨勢。該公司將經營性現金流重新投入業務，進一步加強其在銷售、營銷、醫療事務和法律方面的領導地位。
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
